Scleroderma-related interstitial lung disease

Scleroderma-related interstitial lung disease

Scleroderma-related interstitial lung disease (SSc-ILD) is a pulmonary fibrosing disorder characterized by systemic inflammation and progressive scarring of the lungs that leads to respiratory failure. Although certain immunosuppressive therapies may slow disease progression, current treatment strat...

Full description

Bibliographic Details
Main Authors:	Sally Suliman, Abdalhamid Al Harash, William Neil Roberts, Rafael L. Perez, Jesse Roman
Format:	Article
Language:	English
Published:	Elsevier 2017-01-01
Series:	Respiratory Medicine Case Reports
Subjects:	Pulmonary fibrosis Progressive systemic sclerosis Immunosuppression
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213007117301557

Similar Items

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
by: Vincent Cottin, et al.
Published: (2021-03-01)

Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease
by: Eva Cabrera Cesar, et al.
Published: (2021-07-01)

New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases
by: Arata Azuma, et al.
Published: (2020-07-01)

Progression of fibrosing interstitial lung disease
by: Alyson W. Wong, et al.
Published: (2020-01-01)

Systemic sclerosis sine scleroderma: a case report of anterior uveitis
by: T. Borges, et al.
Published: (2015-06-01)

Diagnosis and treatment of interstitial lung disease in scleroderma systematica
by: L. P. Ananyeva
Published: (2018-06-01)

Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France
by: Vincent Cottin, et al.
Published: (2021-08-01)

Treatment of Systemic Sclerosis Associated Interstitial Lung Disease
by: Iris Yan Ki Tang, et al.
Published: (2020-12-01)

Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis
by: Ludivine Renaud, et al.
Published: (2020-03-01)

Biomarkers in scleroderma: Current status
by: Latika Gupta, et al.
Published: (2017-01-01)

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
by: Ulrike Schmid, et al.
Published: (2021-07-01)

The natural history of progressive fibrosing interstitial lung diseases
by: Martin Kolb, et al.
Published: (2019-03-01)

Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage
by: Laurens J. De Sadeleer, et al.
Published: (2020-06-01)

Progressive systemic sclerosis in a child
by: Arun K De, et al.
Published: (2013-01-01)

Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
by: Padmini Khedoe, et al.
Published: (2020-09-01)

IgG4-related Disease – A Patient with Multiple Organ Involvement
by: Miroslav Průcha, et al.
Published: (2017-09-01)

Serum biomarkers in interstitial lung diseases
by: Anevlavis Stavros, et al.
Published: (2005-07-01)

Interstitial lung disease in systemic sclerosis
by: E.A. Renzoni
Published: (2016-02-01)

Bronchogenic Carcinoma after Lung Transplantation: A Case Report and Literature Review
by: Yeming WANG, et al.
Published: (2011-01-01)

Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
by: Hideaki Yamakawa, et al.
Published: (2018-01-01)

Differences between Acute Exacerbations of Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
by: Paola Faverio, et al.
Published: (2021-09-01)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
by: John N. Shumar, et al.
Published: (2021-05-01)

Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be
by: Tinne Goos, et al.
Published: (2021-03-01)

Interstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies
by: Sakir Ahmed, et al.
Published: (2018-01-01)

Interstitial lung disease in systemic sclerosis (systemic scleroderma)
by: L. P. Ananyeva, et al.
Published: (2021-03-01)

Mitoxantrone in the treatment of multiple sclerosis: a single-center experience
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-06-01)

Interstitial Lung Disease in Systemic Scleroderma, Complicated with Bilateral Pulmonary Aspergilloma: An Unusual Association
by: SAUMEN NANDI, et al.
Published: (2015-12-01)

Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study
by: Tobias Veit, et al.
Published: (2020-10-01)

Drug-Induced Interstitial Lung Disease
by: Wei-I Lee, et al.
Published: (2019-01-01)

Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?
by: Domenico Sambataro, et al.
Published: (2020-04-01)

Role of the Microbiome in Interstitial Lung Diseases
by: Ozioma S. Chioma, et al.
Published: (2021-01-01)

Progressive, subretinal fibrosis mimicking retinal necrosis with poor visual prognosis in sympathetic ophthalmia: A rare finding
by: Kalpana Babu, et al.
Published: (2018-01-01)

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
by: Sabine Adler, et al.
Published: (2018-01-01)

Dyskeratosis Congenita Associated Non-Specific Interstitial Pneumonia
by: Unnati D. Desai, et al.
Published: (2017-01-01)

A case of invasive pulmonary aspergillosis during treatment for acute exacerbation of interstitial lung disease
by: Motoi Ugajin, et al.
Published: (2018-12-01)

Use of leflunomide in patients with chronic hypersensitivity pneumonitis
by: Sungryong Noh, et al.
Published: (2020-07-01)

T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis
by: Gonçalo Boleto, et al.
Published: (2018-08-01)

Echinochrome A Treatment Alleviates Fibrosis and Inflammation in Bleomycin-Induced Scleroderma
by: Gyu-Tae Park, et al.
Published: (2021-04-01)

CORRELATION BETWEEN SYSTEMIC SCLERODERMA AND ORAL SYNDROME
by: Mădălina Matei, et al.
Published: (2020-04-01)

Survival predictors of interstitial lung disease in India: Follow-up of Interstitial Lung Disease India registry
by: Sheetu Singh, et al.
Published: (2021-01-01)